Soufflé Therapeutics Stock
| Valuation | $506.77M1 |
| Valuation Date | Oct 13, 2026 |
| Implied Valuation | n/a |
| Last Price | n/a |
| 52-Week High | n/a |
| 52-Week Low | n/a |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $417.5M |
| Latest Round Amount | $135M2 |
| Latest Round | Series B |
| Funding Rounds | 3 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Soufflé Therapeutics
Soufflé Therapeutics is a biotechnology company that develops siRNA medicines designed to reach specific cell types outside the liver. Its REMEDY (Receptor Mediated Delivery) platform identifies receptors that pull molecules into a target cell and pairs them with antibodies or other binders that carry an siRNA payload to silence a disease-causing gene. The lead candidate, SFL-0821, targets the DUX4 gene in skeletal muscle and entered a Phase 1/2 trial for facioscapulohumeral muscular dystrophy (FSHD) in 2026. Other programs target the phospholamban gene in heart muscle cells for heart failure and an undisclosed target for muscle and metabolic disorders. The company has no approved products and makes money through collaboration and licensing deals with drugmakers, including a 2026 global licensing agreement with Bayer for a heart-targeted siRNA therapy. It was co-founded by MIT professors Robert Langer and Daniel Anderson together with former Alnylam research head Victor Kotelianski.
Invest in Soufflé Therapeutics
Soufflé Therapeutics is a private company, so you can't purchase it with a regular brokerage account. However, the company is listed on Forge.
Forge is a trusted platform for transactions of shares of private companies. It is a subsidiary of The Charles Schwab Corporation.
Invest on ForgeDisclosure: Stock Analysis may be compensated for user sign-ups through Forge links.
News
Soufflé Therapeutics raises $135M Series B
The Watertown-based RNA therapies developer closed a $135 million Series B round led by Juvia Group.
Soufflé gets $135M for three RNA medicines
Endpoints News reported the Oct. 2026 Series B for the Bob Langer-affiliated oligonucleotide startup advancing three experimental programs.
Soufflé Therapeutics Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline Progress
Soufflé closed a $135 million Series B led by Juvia Group, with new investors including TCGX, BB Biotech, Fidelity and Balyasny, to fund clinical studies in FSHD, heart failure and muscle and metaboli...
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration...
Soufflé Therapeutics Gets Venture, Pharma Backing for Genetic Medicines
The biotech startup emerged from stealth after raising nearly $200 million in venture money and said it plans clinical trials for a muscular dystrophy treatment the following year.
Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners
Soufflé, co-founded by Robert Langer, launched with a $200 million Series A and partners including AbbVie, Amgen, Bayer and Novo Nordisk.